Variant
Amersham™ HCPQuant CHO ELISA and Amersham™ Anti-CHO HCP Antibody reduce the risk of unexpected host cell proteins during the transition from generic to specific HCP ELISAs and help maximize the efficiency of your HCP management strategy.
Dilutional linearity throughout purification indicates good sample compatibility and data reliability.
Calculating the same stock concentration of HCP across several dilutions of the same sample is known as parallelism. Parallelism indicates a robust assay that optimizes processes and saves time and resources. Our tests show that you should be able to calculate the same stock concentration of HCP across several dilutions of the same sample — this parameter is also known as parallelism. Parallelism in downstream steps demonstrates a robust assay and enables accurate HCP level tracing — helping you develop a good purification strategy while saving time and resources. The associated figure is #2 ont he carousel above.
Learn more on sample compatibility and parallelism across several downstream purification steps for two cell lines; CHO-K1 and CHO-S in the data file.
We also calculated the lower limit of detection (LLD) as the concentration where the signal is greater than three standard deviations from the mean of the zero standard [0.106 + (3 × 0.003) = 0.115].
We calculated the lower limit of quantification (LLQ) as the lowest concentration for which coefficient of variation (CV) is < 20% and recovery is between 80% and 120%. We determined the LLD and LLQ from eight replicates across two plates.
|
If you leverage different HCP management strategies in process development, standard commercial kits might not mee t your needs. Cytiva’s Amerhsam™ Anti-CHO HCP (supernatant) is a flexible antibody reagent for orthogonal HCP quantification methods. This antibody also supports coverage assays, including fluorescent-based differential in-blot electrophoresis (DIBE™) and affinity-based chromatography methods. |
 |
